BridgeBio Pharma (BBIO) Finished Goods (2025 - 2026)
BridgeBio Pharma (BBIO) reported Finished Goods of $8.0 million for Q1 2026, up 204.89% on a YoY basis from $2.6 million in Q1 2025, and up 23.48% sequentially from $6.5 million in Q4 2025.
BridgeBio Pharma (BBIO) Finished Goods (2025 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 2 years of Finished Goods data on file, last reported at $8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Finished Goods rose 204.89% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (up 204.89% YoY), and the FY2025 full-year result was $6.5 million, changed N/A from the prior year.
- Finished Goods grew to $8.0 million in Q1 2026, from $6.5 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $8.0 million in Q1 2026 to a low of $2.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.04 Mn |
| Dec 31, 2025 | 6.51 Mn |
| Sep 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 5.75 Mn |
| Mar 31, 2025 | 2.64 Mn |